Anatara Lifesciences Ltd Q1 FY27 Activities Report
Key points
- Anti-Obesity project to progress with manufacturing of a demonstration batch of compound AOC
- Received $318,402 R&D tax incentive rebate as anticipated
- Cash at the end of the quarter was $0.551 million
Full summary
Anatara Lifesciences Ltd has announced its activities for the quarter ending September 2026. The company is progressing its Anti-Obesity project by manufacturing a demonstration batch of compound AOC, following positive pre-clinical study results. The company received the anticipated $318,402 rebate from the R&D tax incentive claim. Cash at the end of the quarter was $0.551 million, with net cash inflows of $0.080 million from operating activities and the tax rebate. The company continues to explore business development opportunities and maintain financial prudence.
Guidance
Anatara Lifesciences Ltd received a $318,402 R&D tax incentive rebate as anticipated.
Outlook
Anatara Lifesciences Ltd is progressing with its Anti-Obesity project and exploring further business development opportunities.
Summary generated by a large language model. Please interpret with care.